ArticleScientific reports2022

Aptamer-antibody hybrid ELONA that uses hybridization chain reaction to detect a urinary biomarker EN2 for bladder and prostate cancer.

Eunseon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.